RadiusXR has announced the publication of results from its NOVA study in the journal Translational Vision Science and Technology. The study aimed to compare estimated sensitivities of SITA-Standard to the RATA-Standard algorithm of the Radius head-mounted virtual reality perimeter (VRP) and to measure concordance in glaucoma staging. One hundred adult glaucoma patients (half with suspect or mild glaucoma, half with moderate or severe glaucoma) from 5 clinics performed several 24-2 visual field tests during a single visit, 2 with the Humphrey field analyzer and 2 with the Radius VRP. The study revealed that estimated sensitivities of RATA-Standard are comparable to SITA-Standard between 23 to 40 dB, with a correlation of 0.94 in mean deviation.1
The Radius VRP measures vision within the photopic range, aligning with existing visual field platform standards. This alignment enables consistent clinical training and facilitates comparison to patients' prior examinations, because normative databases and mean deviation/pattern standard deviation plots are based on the photopic range.
"The publication of the NOVA Clinical Trial in TVST reaffirms RadiusXR's position as the leader in visual field testing innovation," said Ammad Khan, RadiusXR's chief executive officer, in a news release. “Our proprietary technology, combined with spatial computing, delivers unparalleled accuracy and precision, revolutionizing the diagnosis and management of ocular conditions."
"Over the past several years, there has been tremendous interest in virtual reality perimetry, recognizing the limitations of traditional bowl-based perimeters," said Nathan Radcliffe, MD, of New York Eye Surgery Center. "However, as these new options have become available, the need for validated studies demonstrating the reliability of these new tests has become obvious. The NOVA study demonstrates the clinical utility and reliability of the RadiusXR system. It yielded impressive results, including a remarkable 0.94 correlation in mean deviation and statistical noninferiority to traditional methods for staging glaucoma. As a direct user of RadiusXR, I can attest to its efficiency and reliability for diagnosing and monitoring visual field defects in patients with glaucoma."
In July 2023, RadiusXR announced it entered into a collaboration and marketing agreement with Glaukos Corporation, a leading ophthalmic pharmaceutical and medical technology company, whereby Glaukos became the exclusive sales agent to market, promote, and solicit orders for RadiusXR in the United States. Radius continues to lead development and commercialization efforts for RadiusXR.
References
- Bradley C, Ahmed IIK, Samuelson TW, et al. Validation of a wearable virtual reality perimeter for glaucoma staging, the NOVA trial: novel virtual reality field assessment. Transl Vis Sci Technol. 2024;13(3):10. doi:10.1167/tvst.13.3.10
